Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Julie Denny
  • March 25, 2014
  • News

The rapidly evolving UC market hots up with new competition in the biologics arena

In March 2006, Johnson & Johnson and Merck’s Remicade (infliximab) became the first biologic therapy approved to treat moderate to severe active UC in the European Union and provided physicians with a new treatment option to achieve disease remission and symptom control in the most severe patients.

However, it took more than six years for a second biologic agent to reach the market. AbbVie’s Humira (adalimumab) was approved in April 2012 and experienced strong uptake from launch, providing physicians with a subcutaneous alternative to Remicade’s IV route of administration.

read more »